Arrowhead Pharmaceuticals, Inc. $ARWR Stock Position Raised by King Luther Capital Management Corp

King Luther Capital Management Corp increased its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 54.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 80,640 shares of the biotechnology company’s stock after acquiring an additional 28,500 shares during the quarter. King Luther Capital Management Corp owned approximately 0.06% of Arrowhead Pharmaceuticals worth $2,781,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in ARWR. Royal Bank of Canada raised its position in shares of Arrowhead Pharmaceuticals by 30.2% during the 1st quarter. Royal Bank of Canada now owns 45,239 shares of the biotechnology company’s stock worth $576,000 after purchasing an additional 10,496 shares during the period. AQR Capital Management LLC acquired a new stake in Arrowhead Pharmaceuticals in the first quarter worth $514,000. Goldman Sachs Group Inc. increased its position in Arrowhead Pharmaceuticals by 34.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after buying an additional 447,456 shares during the period. Empowered Funds LLC lifted its stake in Arrowhead Pharmaceuticals by 6.9% in the first quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock valued at $194,000 after buying an additional 979 shares during the last quarter. Finally, Focus Partners Wealth boosted its holdings in shares of Arrowhead Pharmaceuticals by 1,339.5% during the first quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company’s stock valued at $207,000 after acquiring an additional 15,123 shares during the period. 62.61% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, Director Mauro Ferrari sold 7,530 shares of the company’s stock in a transaction on Friday, December 26th. The stock was sold at an average price of $70.00, for a total value of $527,100.00. Following the completion of the sale, the director owned 69,053 shares in the company, valued at $4,833,710. This represents a 9.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Adeoye Y. Olukotun sold 10,000 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $67.66, for a total value of $676,600.00. Following the transaction, the director directly owned 33,600 shares of the company’s stock, valued at $2,273,376. This represents a 22.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 510,836 shares of company stock worth $33,603,060. 3.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts recently weighed in on ARWR shares. B. Riley Financial increased their price objective on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Piper Sandler restated an “overweight” rating and issued a $110.00 price target (up previously from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th. Bank of America lifted their price target on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 10th. Finally, The Goldman Sachs Group lifted their target price on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $81.67.

Arrowhead Pharmaceuticals Trading Down 0.4%

Arrowhead Pharmaceuticals stock opened at $63.59 on Friday. The firm has a 50 day simple moving average of $66.47 and a 200-day simple moving average of $46.72. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.38 and a quick ratio of 3.38. The stock has a market capitalization of $8.90 billion, a PE ratio of 41.56 and a beta of 1.21. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.60 by ($0.38). The firm had revenue of $264.03 million for the quarter, compared to the consensus estimate of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.Arrowhead Pharmaceuticals’s revenue for the quarter was up 10461.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.39) EPS. As a group, equities research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.